Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells
Authors
Keywords
Sunitinib, Differentiation, Apoptosis, PKC, Bcl-2
Journal
ANNALS OF HEMATOLOGY
Volume 92, Issue 3, Pages 301-313
Publisher
Springer Nature
Online
2012-11-19
DOI
10.1007/s00277-012-1627-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apoptosis: why and how does it occur in biology?
- (2011) Engin Ulukaya et al. CELL BIOCHEMISTRY AND FUNCTION
- The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy
- (2011) P N Kelly et al. CELL DEATH AND DIFFERENTIATION
- Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
- (2010) Alfredo Carrato Mena et al. ANTI-CANCER DRUGS
- Is there a role for differentiating therapy in non-APL AML?
- (2010) H. Phillip Koeffler BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action
- (2010) Susanne C. Miller et al. BIOCHEMICAL PHARMACOLOGY
- Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo
- (2010) Wanjing Ding et al. CANCER LETTERS
- Cdks and cyclins link G1length and differentiation of embryonic, neural and hematopoietic stem cells
- (2010) Christian Lange et al. CELL CYCLE
- Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways
- (2010) F. Yang et al. MOLECULAR CANCER RESEARCH
- Sunitinib Inhibits MEK/ERK and SAPK/JNK Pathways and Increases Sodium/Iodide Symporter Expression in Papillary Thyroid Cancer
- (2010) Mike S. Fenton et al. THYROID
- Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway
- (2010) Szu-Yuan Ping et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
- (2009) H. Xin et al. CANCER RESEARCH
- Differentiation therapy of acute myeloid leukemia: past, present and future
- (2009) Kevin Petrie et al. CURRENT OPINION IN HEMATOLOGY
- Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D3
- (2009) C Nishioka et al. LEUKEMIA
- Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
- (2008) M. A. Sanz et al. BLOOD
- Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone
- (2008) Pawel Zwolak et al. EUROPEAN JOURNAL OF CANCER
- Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
- (2008) Guru Sonpavde et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene
- (2007) Chie Nishioka et al. LEUKEMIA RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started